Guidelines for management of PD for pharmacists
The Canadian guidelines on PD, published in 2012, provide guidance on several aspects of the management of PD, including communication, diagnosis and progression, treatment of motor symptoms and features and treatment of nonmotor symptoms. 1 From these guidelines, information and recommendations most relevant to pharmacists were summarized in the PD guidelines for pharmacists and addressed 4 areas: communication, diagnosis, prognosis and neuroprotection and treatment of both motor and nonmotor features of PD. 1, 6 The objective of the present article is to focus attention on those aspects of the treatment of PD that pharmacists can address in collaboration not only with patients' physicians but also with other providers involved in the circle of care. With this objective in mind, we also discuss drug-induced parkinsonism and provide additional details PRACTICEGUIDELINES related to pharmacotherapy to complement the PD guidelines for pharmacists. Finally, we review 2 publications detailing the impact of community pharmacy on providing care to patients with PD.
Drug-induced parkinsonism (DIP)
Diagnosis of PD is guided by the presentation of clinical symptoms; there is no diagnostic test that clearly identifies PD. 1 Additionally, where diagnosis is difficult to ascertain from the clinical presentation, other forms of parkinsonism, such as multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration, have to be ruled out. Therefore, patients who present to a community pharmacy with symptoms indicative of PD should be referred to their family physician for assessment and diagnosis and, usually, referral to a specialist. 1, 6 Community pharmacists can contribute to the assessment and diagnosis of the patient by reviewing current medications to determine the likelihood of drug-induced parkinsonism (DIP) and reporting the potential relationship of presentation of PD symptoms with the initiation of any medications known to be likely causes of DIP to the family physician. Medications are the second most prevalent cause of parkinsonism (making up 20%-56% of all cases), with almost 7% of patients presenting with DIP misdiagnosed with PD. [7] [8] [9] Drugs frequently associated with DIP include antipsychotics, both typical and atypical agents, some cardiovascular medications such as flunarizine and antiemetics such as metoclopramide or trifluoperazine (see Table 2 for drugs commonly associated with DIP). Review of the temporal relationship between symptom onset and initiation of an offending medication (onset of symptoms within 1-3 months) may guide PRACTICEGUIDELINES clinicians in the diagnosis of PD. 7, 9 Although not always a reliable indicator, the presentation of motor symptoms is usually asymmetric in idiopathic PD but symmetric in DIP. [7] [8] [9] Additionally, clinical response to levodopa is usually excellent in idiopathic PD but poor in DIP. [7] [8] [9] Finally, withdrawal of the causative agent may result in amelioration of motor symptoms in 75% to 80% of patients with DIP but not in idiopathic PD, although this may take several months. [7] [8] [9] The use of these medications may also unmask the underlying PD. [7] [8] [9] 
Treatment
The discovery of curative, neuroprotective or disease-modifying treatments with PD has been elusive, and currently the goal of treatment is to alleviate the symptoms of PD. 1, 5 A review of the results of clinical trials investigating pharmacological agents for neuroprotection in PD has led the authors of the Canadian PD guidelines to recommend against use of vitamin E, coenzyme Q10 and monoamine oxidase B inhibitors explicitly for neuroprotection. 1, 6 There is insufficient evidence to support or refute the use of amantadine, and no long-term evidence that indicates that levodopa is neuroprotective. 1, 6 Several different modalities, including pharmacotherapy, surgery, physiotherapy, occupational therapy, speech therapy and exercise, may be used to produce therapeutic benefit in patients with PD. 1, 6 This article focuses on the use of pharmacotherapy for the treatment of PD and complements the information previously presented in the PD guidelines for pharmacists. 6 The initiation of pharmacotherapy is guided by patients and usually is indicated when symptoms impair functionality, quality of life or employment or lead to embarrassment in social situations. 1, 5, 6, 10 The choice of drug used to initiate treatment should be based on the clinical characteristics (presenting PD symptoms, age, comorbid conditions, drug-drug interactions with other agents and adverse effects of medications) and lifestyle characteristics (impact of symptoms on quality of life and ability to work, affordability of medications) of the patient and should include the patient in the decision-making process once he or she has been informed of the short-and long-term consequences, both positive and negative. 1, 5, 6, 10 Given the loss of dopaminergic neurons, key pharmacological options for the treatment of PD are related to 1 of 2 modalities 10 :
Replacing or increasing dopamine concentrations intracranially 2. Agonistic activity at dopamine receptors
Monoamine oxidase B inhibitors, levodopa with dopa decarboxylase inhibitors and dopamine agonists are the primary drugs of choice for initiating treatment. Amantadine may be used in early PD but is not a drug of choice, while anticholinergics are not drugs of choice but may be used in young patients with tremor-predominant early PD; the use of these agents in elderly patients is limited by the potential for detrimental cognitive effects. 1 Finally, although beta-blockers may be used to treat postural tremors in selected patients, these agents are not drugs of first choice. 1 Levodopa has been demonstrated to be a very effective drug for the treatment of PD. 1 It is metabolized in the periphery by dopamine decarboxylase to dopamine, resulting in gastrointestinal side effects (nausea and vomiting) and orthostatic hypotension. 1, 10 Additionally, dopamine does not penetrate the blood-brain barrier. To minimize side effects and increase the amount of dopamine in the brain, levodopa is formulated in combination with 1 of 2 decarboxylase inhibitors, carbidopa or benserazide. Levodopa/carbidopa is also available in combination with a catechol-O-methyl transferase inhibitor, entacapone, which decreases the metabolism of levodopa into another metabolite, 3-O-methyl dopa, through a different pathway. 10 The coadministration of carbidopa or benserazide decreases the incidence of nausea and vomiting; however, in some patients, administration with food may provide further relief, although there are several caveats to consider in more advanced PD:
Dietary protein competes with levodopa
for absorption from the intestine; therefore, if the patient is advised to administer levodopa with food, he or she should also be advised to avoid meals high in protein content when ingesting levodopa. 2. Absorption may be variable or delayed with meals, therefore, if the patient complains of delayed onset of effect or variability in effectiveness, he or she should be advised to take levodopa 1 hour before or after eating. 10 Levodopa should also be initiated at a small dose and titrated up to an initial dose of 100/25 PRACTICEGUIDELINES mg 3 times per day or lower for elderly patients, to mitigate these side effects. If these strategies do not prevent nausea and vomiting, domperidone 10 mg before meals, up to 3 times per day, may be suggested. 10 Absorption of the sustainedrelease formulation of levodopa is highly variable, and this formulation is not recommended for management of gastrointestinal side effects. 10 Long-term levodopa therapy may be associated with dyskinesias and motor fluctuations, such as "end-of-dose deterioration" or "wearing off, " unpredictable "on-off " and "delayed on, " which can significantly worsen patients' quality of life. 1, 5, 10 Suggestions for the management of these side effects are provided in Table 3 . Other side effects include orthostatic hypotension, neuropsychiatric side effects such as hallucinations, confusion, impulse control disorders (e.g., hypersexuality, gambling) and somnolence, although these are more common with dopamine agonists. 1, 6, 5, 10 Dopamine agonists are not as potent as levodopa but are more effective than the other agents used to treat PD. 1 Ergot-derived dopamine agonists, such as bromocriptine, have fallen out of favour due to the potential for serious side effects such as serosal membrane fibrosis and erythromelalgia. Non-ergot-derived dopamine agonists, pramipexole and ropinirole, are used with greater frequency, typically in younger patients given the higher frequency of side effects in older patients. 1, 10 Dopamine agonists activate specific types of dopamine receptors and have some theoretical advantages over levodopa: they do not require conversion to dopamine for activity, do not compete with dietary protein for absorption and have longer half-lives than levodopa. 1, 10 Adverse effects include gastrointestinal side effects, orthostatic hypotension, hallucinations, impulse control disorders (especially in younger patients), leg edema and sleepiness. 1, 5, 10 Initiation of either dopamine agonist at a small dose with gradual titration should minimize peripheral side effects and allow tolerance to develop. 1, 10 Both dopamine agonists and levodopa have been associated with reports of "sudden sleep" attacks; however, they occur more frequently with dopamine agonists. These attacks, which occur without warning, are likely related to excessive daytime sleepiness. 10 Monoamine oxidase B inhibitors, selegiline and rasagiline, irreversibly inhibit the metabolism of dopamine, thereby increasing the concentrations of dopamine in the brain. 1, 10 Both agents are effective for mild symptoms in early PD and are generally well tolerated. 1, 10 Selegiline is metabolized to amphetamine and methamphetamine and can produce insomnia if taken later in the day. Rasagiline appears to be the more potent of the 2 agents and is not metabolized to amphetamine or methamphetamine. Both agents may be used as monotherapy for symptom relief earlier in the disease process, but rasagiline may be used as an adjunct to levodopa in the later stages of PD to reduce off time. 1, 10 However, patients should be monitored for dyskinesias and neuropsychiatric side effects when these agents are used as adjunctive treatment. 1, 10 The use of anticholinergic agents, trihexyphenidyl and benztropine, is limited to cognitively intact patients younger than 60 years of age who present with tremor-predominant PD. 1, 5, 10 As with other agents, a small dose should be initiated and the dose should be gradually titrated to an effective level. 10 As expected with any anticholinergic, patients may present with side effects such as confusion, memory impairment, hallucinations, sedation, dry mouth, blurred vision, constipation and orthostatic hypotension. 10 While some patients may tolerate sedation, dry mouth and blurred vision, the appearance of cognitive impairment should deter the use of these agents. Orthostatic hypotension may be responsive to treatment with fludrocortisone or midodrine. 10 Anticholinergics should be withdrawn slowly to prevent acute exacerbation of parkinsonian symptoms. 10 The mechanism of action of amantadine in PD is not known. It is an N-methyl-d-aspartate (NMDA) antagonist and likely has dopamine agonist as well as anticholinergic effects. 1, 10 It may be used in early PD but is not the drug of first choice and is generally used in the later stages of PD for the treatment of levodopainduced dyskinesias. 1, 5, 10 Similar to other agents with dopamine agonist activity, it has side effects including nausea, hallucinations, confusion and orthostatic hypotension. 10 Patients may also report dry mouth, blurred vision and sedation as well as other anticholinergic side effects. As amantadine is renally cleared, the dose should be limited in elderly patients and the drug should be avoided or used only with great caution in others with renal impairment. Additionally, patients should be closely monitored for livedo reticularis. Ankle edema can limit treatment. 10 
PRACTICEGUIDELINES

Autonomic
Constipation • Improve dietary fiber and fluid intake.
• Improve physical activity.
• If on anticholinergic agents, discontinue.
• Initiate stool softeners, bulk-forming laxatives or enemas; limit use of bisacodyl.
• Consider domperidone if constipation related to decreased motility associated with PD.
Orthostatic hypotension
• Reduce/discontinue antihypertensive medications.
• Reduce/discontinue other medications that can cause hypotension.
• Advise patients to change positions (sitting from sleeping position or standing from sitting position or after a meal) very slowly. • Advise patients to avoid large meals, alcohol, excessively warm areas.
• Increase fluids, increase salt intake.
• Elevate head on multiple pillows or elevate head of bed. 
PRACTICEGUIDELINES
Monotherapy with a single agent may produce excellent results for the first few years of treatment; however, the majority of patients will eventually require polytherapy. Frequent monitoring of effectiveness and safety is necessary in order to determine the most optimal doses, optimal times of administration and appropriate adjunctive treatment as PD progresses. Pharmacists may encounter patients with PD or their caregivers with greater regularity than do other health professionals, given the fixed dispensing intervals for medications. This presents pharmacists with an opportunity to use their knowledge of pharmacotherapy, as well as long-standing relationships and comprehensive appreciation of their patients' drug therapy, to work collaboratively with patients and other health care providers. In this manner, pharmacists can collaboratively help determine the appropriate drug treatment as well as monitor and adjust pharmacotherapy to improve safety, effectiveness, adherence and attainment of patient-specific goals of therapy (Box 1). Pharmacists are also well placed to provide ongoing educational sessions with the patients.
Review of community pharmacy care in patients with PD
Two clinical trials have investigated the impact of community pharmacist involvement in the treatment of patients with PD. [11] [12] [13] Mynors et al. 11 designed a prospective pilot study in order to determine the feasibility of a community pharmacist intervention with patients with PD in the United Kingdom. Participants were asked to complete validated questionnaires evaluating their satisfaction and adherence upon entry into the study and after 6 months. Community pharmacists were recruited and trained to consult with patients with PD in order to elicit and address medication-related problems as appropriate. The majority of consultations among the 230 participants were carried out in the community pharmacy, while 40% were conducted in the patients' homes. Patient satisfaction with information on medicines improved significantly, as did patient mobility. Furthermore, 61% of the participants reported an improvement in their knowledge of PD, 63% reported an improvement in knowledge of their medicines and 70% claimed greater benefit from their drugs after participation in the trial. Mean adherence scores did not change significantly from baseline, although patients demonstrated high levels of compliance at both baseline and end of study.
The second study investigating the impact of community pharmacist involvement in the management of PD was conducted in 32 German pharmacies. 12, 13 PRACTICEGUIDELINES the disease-specific and quality-of-life outcome measures improved significantly in the pharmacy arm compared with the nonpharmacy arm. Additionally, use of inappropriate drugs improved significantly in the pharmacy arm compared with the nonpharmacy arm. 12 A total of 331 drugrelated problems were identified, and pharmacists recommended 474 interventions for the 113 patients recruited to the pharmacy arm. The most frequently identified drug-related problem was untreated indication (26.3%), followed by symptoms of an adverse drug reaction (12.4%), unsuitable time of intake (10%), underdosage (9.7%) and drug interactions (9.4%). Forty-eight percent (48%) of the drug-related problems were associated with anti-parkinsonian medication, most frequently levodopa and dopamine agonists. An evaluation of the clinical significance of drug-related problems indicated that 4.5% were extremely important, 27.2% were of major importance, 29% were of moderate importance and 39.3% were of minor importance. The interventions most frequently performed by pharmacists were providing patients with special treatment advice (19.6%), addressing concerns with compliance (15.6%) and addressing adverse drug reactions (11.6%). 13 Other interventions included addressing drug interactions, inappropriate dosages, inappropriate drug choice, referrals to physicians and specialist clinical centres, contacting the physician and interviewing patients and caregivers. 13
Summary
The practice of community pharmacy is evolving from one of distribution of prescribed products to one of patient-centred care through the provision of pharmaceutical care and focus on improvement of health outcomes. Pharmacists are well placed and well trained to assess and manage medical conditions such as PD through collaboration with patients and other health care professionals. The present article, in conjunction with the Canadian guidelines on PD 1 and the PD guidelines for pharmacists, 6 will enable pharmacists to collaborate with health care professionals and patient advocacy organizations such as Parkinson Society Canada to facilitate changes in drug therapy, monitor for outcomes and empower their patients to improve their knowledge, therapeutic outcomes and quality of life. ■ From the University of Waterloo School of Pharmacy, Kitchener, Ontario. Contact t5patel@uwaterloo.ca.
